Simplify Logo

Full-Time

Principal Scientist

LNP Development

Posted on 6/18/2024

Beam Therapeutics

Beam Therapeutics

201-500 employees

Develops precision genetic medicines using base editing

Hardware
Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Python
R
SQL
Requirements
  • PhD or MS in Pharmaceutical Sciences, Chemical engineering, Bioengineering or related field with of drug product and CMC development experience (PhD 8+ years or MS 18+ years)
  • Deep understanding of late stage product development activities
  • Product development experience especially in nucleic acids and drug delivery is preferred
  • Comprehensive knowledge and understanding of solubility, phase-separation, colloidal stability, electrostatic and hydrophobic interactions
  • Familiarity with ultrafiltration and aseptic unit operations for sterile drug product manufacture
  • Knowledge of statistical techniques and concepts
  • Experience using statistical computer languages (R, Python, SQL, etc.) to manipulate data and draw insights from large data sets
  • Excellent computational, written, and verbal communication skills
  • Strong organizational abilities
  • Ability to work with a diverse group of scientists and engineers
  • Ability to adapt to increasing scope and complexity of work brought on by growth/change
Responsibilities
  • Collaborate with scientists in application of statistics to Drug Product Development
  • Design and execute experiments for formulation and process development
  • Contribute to the Chemistry, Manufacturing and Controls (CMC) strategy
  • Lead technology transfer projects
  • Generate data for regulatory filings
  • Develop and maintain effective working relationships with other division groups

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Unlike many competitors, Beam Therapeutics emphasizes collaboration with pharmaceutical companies and research institutions, which helps them secure funding and advance their projects. Their goal is to advance scientific research and deliver effective, long-lasting treatments for patients.

Company Stage

IPO

Total Funding

$689M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

1%

1 year growth

-8%

2 year growth

-7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Beam Therapeutics' innovative base editing technology has the potential to revolutionize the treatment of genetic disorders, offering hope for lifelong cures.
  • The company's strong pipeline, including early-stage studies for sickle cell disease, positions it well for future growth and breakthroughs.
  • Significant investments and partnerships, like the recent $250 million deal with Eli Lilly, enhance Beam's financial stability and research capabilities.

What critics are saying

  • The recent retirement of CFO Terry-Ann Burrell and the layoff of 20% of staff could lead to operational disruptions and affect company morale.
  • Beam's focus on early-stage studies means that its treatments are still years away from commercialization, posing a risk to short-term revenue generation.

What makes Beam Therapeutics unique

  • Beam Therapeutics leverages base editing technology, which allows for precise genetic modifications, setting it apart from traditional gene-editing methods like CRISPR.
  • The company's focus on developing lifelong cures for genetic disorders, rather than temporary treatments, distinguishes it in the biotechnology sector.
  • Beam's strategic partnerships and licensing agreements, such as the $250 million deal with Eli Lilly, provide significant financial backing and collaborative opportunities.
INACTIVE